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Abstract 
Purpose: To evaluate the in vivo effects of ITC as an immunomodulator on various immunological 
mediators, including cytokines, chemokines and growth factors in pulmonary homogenates.  
Methods: Two experimental groups consisting of 25 BALB/c mice each were used: (a) PBS-treated 
mice and (b) ITC-treated mice (1 mg/mouse/day). The animals were treated daily via gavage for 8 
weeks. Five mice from each group were sacrificed at 0, 4, 8, and 12 weeks and cytokine levels 
assessed in the supernatants of lung macerates using the Bio-Plex system. Five lungs from each 
experimental group, after 8 weeks of treatment, were used for histopathological analysis.  
Results: Compared with the control group, ITC-treated mice showed significant changes in the 
pulmonary levels of 50 % of the molecules evaluated: IL-4, IL-10, IL-12p70, IL-13, TNF-α, eotaxin, MIP-
1α, MIP-2, and LIF were significantly upregulated. In contrast, IL-1β, IL-15, IL-2, IL-1α, and VEGF were 
downregulated.  
Conclusion: Although histopathological examination did not show changes in lung cell infiltrates, ITC 
exerted a marked immunomodulatory effect at the pulmonary level in healthy BALB/c mice. 
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The marked increase in the incidence of fungal 
infections in recent decades, principally due to 
the growing number of patients with AIDS and 
organ transplants, has awakened interest not 
only in developing new antifungal drugs but also 
in evaluating the effects that current antifungals 
have on the host immune response [1-3]. It is 
important to ensure that these agents per se do 
not exert negative effects on the host immune 
system. 
 
Itraconazole (ITC), a broad-spectrum azole 
antifungal agent, is used widely to prevent and 
treat some pulmonary fungal infections as well as 
other medically important fungi, causing 
superficial, subcutaneous, and systemic 
infections in humans [1]. The mechanism of 
action of ITC is based on inhibiting 14-α-sterol 
demethylase, a cytochrome P450 fungal enzyme 
essential for the biosynthesis of ergosterol, an 
important component of the fungal cell 
membrane. [4]. ITC is considered fungistatic, 
rather than fungicidal, and its action should be 
complemented by the host immune response in 
such a way that the infectious agent is eliminated 
[5]. 
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During a fungal infection, the host immune 
response against the pathogen occurs at 
different levels, with increasing specificity over 
time; phagocytic cells, macrophages, dendritic 
cells, and neutrophils are responsible for innate 
immunity, representing the first line of defense 
against fungal pathogens. These cells produce 
and secrete a wide array of molecules, such as 
chemokines, growth factors, and pro- and anti-
inflammatory cytokines. Expression of these 
molecules is an important step in the 
development of adaptive immunity, which 
depending on the profile expressed, may 
constitute a protective immune response [6,7]. 
 
In addition to their antimicrobial actions, certain 
drugs, particularly antibiotics, have direct 
modulating effects on the immune response, as 
shown by both in vitro and in vivo studies. 
Although several papers have described the in 
vitro effects of some antifungals on the activities 
of macrophages, monocytes, and neutrophils 
from animals and humans [2,3,7,8], little is 
known about the in vivo effects of antifungal 
drugs. 
 
Louie et al [9] suggested that the efficacy of 
certain antifungal agents may be related to their 
ability to induce cytokine production. Fidan et al 
[10] showed that fluconazole, an antifungal drug 
used frequently to treat Candida infections, 
increased the levels of chemokines, such as 
CCL3 and CCL4, in the supernatants of human 
mononuclear cell cultures. 
 
Because antifungal drugs are widely used in 
patients who are immunocompromised to some 
degree, it is important to determine the possible 
effects of these therapies on the immune system 
in vivo [4,11]. Given that little is currently known 
about the modulating properties of ITC, the aim 
of the present study was to evaluate the potential 
immunomodulatory activity of this antifungal drug 
on the pulmonary levels of 28 molecules with 






In total, 50 isogenic male BALB/c mice, 6 - 7 
weeks old, weighing 18 - 20 g, were obtained 
from the breeding colony of the Corporación para 
Investigaciones Biológicas (CIB). Mice were bred 
and maintained in a micro-isolator system (Super 
Mouse 1800) at 22 °C under a 12/12 h light/dark 
cycle. The animals were provided sterile food 
and acidified water (pH 3.0 - 3.5) in sterilized 
bottles ad libitum and sterile bedding. All animal 
handling and maintenance procedures used 
were approved by the Ethics Committee of CIB 
(Act.092), and in accordance with the guidelines 
of NIH Laboratory Animal Care [12]. 
 
Drug, dosing and trial design 
 
The animals were divided into two groups (PBS 
control vs. ITC treatment) of 25 mice each. The 
ITC was administered at 1 mg/mouse/day, the 
dose necessary to achieve serum levels of 1 
μg/mL, as confirmed using a bioassay measuring 
blood levels of ITC. Lower levels of ITC have 
been associated with antifungal therapy failure 
[13]. Mice received 100 µL PBS or 100 µL ITC 
oral solution (Sporanox Janssen-Cilag S.A) daily 
for 8 weeks via gavage, and five members of 
each group were sacrificed at 0, 4, 8, and 12 
weeks; the 12th week corresponded to a post-
treatment follow-up interval of 4 weeks. 
 
Sacrifice of animals and sample processing  
 
At each of the time points evaluated, five animals 
from each group were euthanized by 
intraperitoneal injection of 1 mL 2.5 % sodium 
pentothal (Sandoz Laboratories, Kundl, Austria 
[14]. After the death of the mice, the lungs were 
removed and homogenized individually using a 
tissue grinder (Tissue Tearer model 985-370, 
Biospec Products) in 2 mL of solution containing 
a protease inhibitor cocktail (pepsin 0.1 µM, 
leupeptin 0.1 µM, phenylmethyl sulfonide fluoride 
1 mM, N-tosyl-L-phenylalanine chloromethyl 
ketone 0.2 mM, and (α)-p-methyl L lysine 
chloromethyl ketone 0.1 mM (Sigma), plus 
ethylenediaminetetra-acetic acid 1 nM (Merck, 
Germany)). Homogenates were stored on ice 
and then centrifuged (3000 rpm, 15 min, 4 °C), 
and the supernatants were removed and stored 
at −70 °C until assayed [14].  
 
To evaluate any potential cellular inflammatory 
responses, five lungs from both ITC-treated and 
PBS-treated mice after 8 weeks of treatment 
were perfused and fixed in 10 % 
formaldehyde−PBS and embedded in paraffin 
wax. Coronal 5 µm thick sections of the entire 
lung were stained with hematoxylin and eosin 
(H&E) for histopathological analysis. 
 
Measurement of molecules with immunologi-
cal activity 
 
Supernatants of lung homogenates were thawed 
immediately prior to being used. The protein 
concentration was determined in each sample by 
the Bradford method (Bio-Rad Laboratories) 
following the manufacturer’s protocol and then 
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normalized to 1 mg/mL. A magnetic bead-based 
multiplex assay was used to quantify the levels of 
multiple molecules in each normalized sample 
following the manufacturer’s instructions (Bio-
Plex Pro-Mouse Assay, Bio-Rad Inc., CA, USA). 
The following molecules were measured: IL-1α, 
IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL 
12(p40), IL-12(p70), IL-13, IL-15, IL-17, IFN-γ, 
TNF-α, eotaxin, granulocyte colony stimulating 
factor (G-CSF), granulocyte-monocyte colony 
stimulating factor (GM CSF), macrophage 
inflammatory proteins 1α, 1β, and 2 (MIP-1α, 
MIP-1β, MIP 2), fibroblast growth factor (FGF), 
vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), 
keratinocyte chemoattractant (KC), monokine 
induced by gamma interferon (MIG), and 
leukemia inhibitory factor (LIF).  
 
Levels were determined using a multiplex array 
reader from Luminex Instrumentation System 
(Bio-Plex Workstation from Bio-Rad 
Laboratories), and each molecule’s concentration 
was calculated using Bio-Plex Manager 
Software. The results are expressed in pg/mg 
protein. 
 
Statistical analysis  
 
Comparisons between experimental groups 
(PBS- vs. ITC-treated) were performed for each 
time point (0, 4, 8, and 12 weeks) using a two-
tailed Student’s t test with ‘R’ software. 
Differences between groups were considered 
statistically significant at p ≤ 0.05 and highly 
significant at p ≤ 0.01. The immunomodulatory 




ITC-treatment induced immunomodulatory 
effects at the pulmonary level 
 
ITC treatment exerted a significant modulatory 
effect on 14/28 (50 %) of the immunological 
molecules evaluated. Three different patterns of 
the pulmonary levels of these molecules were 
also observed.  
 
Changes observed from the first evaluation time 
point until the end of ITC treatment: This pattern 
was observed for IL-1β, which decreased 
significantly during ITC treatment compared with 
PBS treatment. However, the cytokine returned 
to normal levels upon completion of treatment. 
 
Changes observed from the first evaluation time 
point until 4 weeks post ITC treatment 
completion: This pattern was observed for seven 
molecules, most of which were increased 
significantly compared with the control group; 
only IL-15 levels decreasing during ITC treatment 
(Table 1, Figure 1). 
 
Changes observed only at the end of ITC 
therapy 
 
Six molecules did not exhibit changes in their 
pulmonary levels until after 8 weeks of treatment. 
Some were increased, while others decreased 
significantly. The levels of IL-1α and MIP-2 
remained altered even at 4 weeks post treatment 
completion (Table 2, Fig. 2). 
 
Table 1: Changes observed from the first evaluation time point to 4 weeks post ITC treatment completion 
 
Molecule   Duration of treatment  Follow up  
[pg/mg protein] Treatment 0 w 4 w  8 w 12 w   
IL-4 PBS 0.7 0.8 0.8 0.9 ↑ ITC   1.2 ** 1.1 * 1.4 *** 
 IL-10 PBS 1.5 2.6 2.8 3.2 ↑ ITC   6.3 *** 4.6 ** 6.3 *** 
IL-12p70 PBS 22.6 23.3 19.6 25.4 ↑ ITC   41.8 ** 32.5 ** 43.3 * 
IL-13 PBS 82.3 96.3 100.2 103.0 ↑ ITC   159.1 ** 156.4 ** 185.6 *** 
TNF-α PBS 21.0 25.8 25,1 32.6 ↑ ITC   47.8 * 49.6 *** 62.0 *** 
Eotaxin PBS 86.8 137.8 121,2 155.9 ↑ ITC   291.8 * 304.6 *** 339.8 ** 
IL-15 PBS 41.7 54.3 58.8 61.1 ↓ ITC   19.6 * 16.7 *** 36.0 * 
Differences determined by t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001. ↑ Increase or ↓ decrease versus PBS 
control 
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Figure 1: Representative graph of the changes observed in the affected molecules from the first evaluation time 
point to 4 weeks post itraconazole (ITC) treatment completion. Mice received 100 µL PBS (controls) or 100 µL 
ITC daily for 8 weeks via gavage; the 12th week corresponds to a post-treatment follow-up period of 4 weeks. 
Values are expressed as pg/mg lung protein and represent the means from five experiments. Differences with 
respect to PBS-treated animals were analyzed by t-test, and statistical significance was set at P < 0.05 
 
Table 2: Changes observed only at the end of ITC therapy 
 
Molecule   Period of treatment  Follow up  
[pg/mg protein] Treatment 0 w 4 w  8 w 12 w   
IL-2 PBS 4.6 5.1 6.2 6.9 ↓ ITC   3.7 NS 4.0 * 9.4 NS 
 IL-1α PBS 4.9 8.1 9.3 14.1 ↓ ITC   5.4 NS 5.4 * 7.9 ** 
MIP-1α PBS 34.1 47.1 36.4 54.5 ↑ ITC   77.7 NS 48.4 * 58.8 NS 
MIP-2 PBS 14.3 17.7 3.8 6.9 ↑ ITC   36.1 NS 24.9 * 19.5 * 
 LIF PBS 4.8 4.9 2.5 3.9 ↑ ITC   8.9 NS 5.7 * 3.8 NS 
VEGF 
PBS 565.6 814.3 588.0 812.6 
↓ ITC   669.2 NS 273.6 ** 471.5 
NS 
Differences determined by t-test. * P < 0.05 and ** P < 0.01, NS: not  
significant. ↑ Increase or ↓ decrease versus PBS control 
 
 
Figure 2: Representative results observed for those molecules modulated only after itraconazole (ITC) treatment 
completion. Mice received 100 µL PBS (controls) or 100 µL ITC daily for 8 weeks via gavage; the 12th week 
corresponds to a follow-up period of 4 weeks post treatment. Values are expressed in pg/mg lung protein and 
represent the means from five experiments. Differences were determined by t-test and were considered 
statistically significant at P < 0.05 
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Of the 28 molecules evaluated, 14, including 
cytokines, growth factors, and chemokines (IL-3, 
IL-5, IL-6, IL-9, IL-17, IL-12p40, G-CSF, GM-
CSF, FGF, IFN-γ, MIP-1β KC, MIG, and PDGF), 
showed no changes induced by ITC treatment at 




Coronal sections of whole lungs stained with 
H&E were viewed by light microscopy, and the 
presence of any pulmonary alterations and/or 
inflammation possibly resulting from ITC 
treatment was examined. In both PBS-treated 
(control) and ITC-treated mice, the histology of 
the lungs was normal and indistinguishable 
between the groups. The airways remained 
clear, with the alveoli and alveolar ducts intact 
and no evidence of damage, alteration, 
inflammation, or cell migration. Furthermore, we 
observed no bronchiolar, peribronchiolar, or 
perivascular inflammation in either group. 
Representative lung sections from PBS-treated 




Figure 3: Representative histological sections from 
lungs of PBS-treated (A) and itraconazole (ITC)-
treated (B) mice after 8 weeks of treatment consisting 
of 100 µL PBS or 100 µL ITC oral solution daily via 
gavage, respectively. Structures noted in the 
pulmonary histological samples are labeled: airway 
(a), alveoli (b), alveolar ducts (c), and blood vessels 
(d). H&E staining and magnification ×20 
DISCUSSION 
 
Compared with PBS control group, ITC treatment 
had a significant modulating effect on the 
pulmonary levels of 50 % of the molecules 
evaluated in healthy BALB/c male mice. Some of 
these molecules changed at the beginning or end 
of ITC treatment (IL-1α, IL-1β, IL 2, MIP-1α, MIP-
2, LIF, and VEGF), while others showed changes 
throughout the ITC treatment course and even 4 
weeks after treatment completion (IL-4, IL-10, IL-
12p70, IL-13, IL-15, TNF-α, and eotaxin). 
 
ITC is a synthetic triazole antifungal agent that is 
widely used because of its broad antimycotic 
spectrum [1,2,4,9]. Like other triazoles, it is a 
heterocyclic compound containing a five-
membered diunsaturated ring structure 
composed of three nitrogen atoms and two 
carbon atoms at non-adjacent positions. This 
triazole scaffold is extremely versatile and has a 
broad spectrum of pharmacological activities 
[15]. Recently, there has been interest in the 
non-antifungal effects of this group of drugs, 
because knowledge of these properties could 
enhance both their clinical usefulness and 
therapeutic efficacy [3]. 
 
Several papers describing the activity of 
antifungal drugs on the immune system have 
been published, most based on in vitro studies 
[7-10]. Regarding the immunomodulatory effects 
of azoles, the results have been conflicting. 
Vaughn et al [16] showed that aerosolized ITC 
given to ICR mice for 12 days did not have 
inflammatory or modulatory effects in the lungs; 
they evaluated IL-12 levels in bronchoalveolar 
lavage fluid and found no change compared with 
control animals [16]. However, in a review of the 
immunomodulatory activity of antifungal drugs, 
Yamaguchi et al [3] suggested that azoles, in 
general, tend to act as immunosuppressants. 
Consistent with this, our results showed that 
levels of IL-1β and IL-1α were decreased 
significantly in the lungs of ITC-treated mice; 
these cytokines are considered important 
molecules in antifungal host defenses and key to 
induction of the Th1 protective response [6,17]. 
Additionally, several reports have suggested that 
the production of Th2 cytokines (IL-4, IL-5, IL-10, 
and IL-13) is associated with susceptibility to 
pulmonary fungal infections [18]. Our results 
showed that pulmonary levels of IL-4, IL-10, and 
IL-13, considered anti-inflammatory molecules, 
were higher during and even 4 weeks after the 
end of ITC treatment in mice. 
 
Although the histopathological analysis showed 
no change in pulmonary cellular infiltrates, three 
molecules (MIP-1α, MIP-2, and eotaxin) 
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considered chemokines in polymorphonuclear 
leukocytes (PMNs) were upregulated after ITC 
treatment compared with PBS-treated mice. 
Because PMNs are an important component of 
the host defense against opportunistic fungi, their 
suppression could diminish the ability of the host 
to control this type of infection [19,20]. 
Sources of these pulmonary cytokines may 
include several cell types, such as mast cells, 
epithelial cells, T cells, alveolar macrophages, 
and even eosinophils, which produce IL-4 and IL-
5 [21-22]. We suggest that the pulmonary 
microenvironment may be defined by the 
presence of local effector cells and the cytokine 
milieu that they create, or, as observed in this 
study, by the use of certain medications that can 
influence the type of response generated. The 
precise mechanism(s) by which ITC exerts its 
effects on the immune system and whether the 
corresponding changes have clinically significant 
results remain unclear. One possible mechanism 
is the ability of ITC to inhibit cytochrome P450 
enzyme systems [23]. ITC has been shown to 
inhibit CYP450 enzyme 5-lipooxigenase dose-
dependently, interfering with the synthesis of 
leukotriene B4 (LTB4), the major product of 
arachidonic acid metabolism, which has been 
implicated as a potent mediator of inflammatory 
processes and immunoregulation [23]. In 
addition, it has been demonstrated in primary 
cultures of human hepatocytes that some azolic 
drugs are antagonists of the human 
glucocorticoid receptor (GR), which belongs to 
the family of steroid/thyroid receptors. GR 
regulates many cellular functions such as 
homeostasis, cell differentiation, proliferation, 
and host immune defenses [24]. These 
properties could explain the antiinflammatory 
activity of ITC observed in chronic 
granulomatous disease [25] and allergic 
bronchopulmonary aspergillosis [26]. 
Additionally, given the molecular structure of 
imidazole antimycotics, ITC has been shown to 
have more potent anti-inflammatory activity than 
those of ketoconazole, fluconazole, and 
voriconazole [18]. Recently, Lindstedt et al 
evaluated the therapeutic effects of a triazole 
derivative (ST1959) on an autoimmune disease; 
they found that this triazole decreased human T 
cell proliferation and inhibited the expression of 
some cytokines at the transcriptional level, 
specifically by inhibition of the nuclear 





The findings indicate that ITC, at a serum level of 
1 μg/mL (therapeutically achievable concen-
tration), may exert a marked immunomodulatory 
effect, accompanied by a slight 
immunosuppressive tendency at the pulmonary 
level in healthy male BALB/c mice. These results 
suggest an alternative, albeit unexplored, 
mechanism of ITC-mediated immunomodulation. 
Further studies evaluating more time points and 
parallel pharmacokinetic analyses are needed in 
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